Contact
searchSearch
HMP Global

Multiple Myeloma Topic Center

Featured Article

News
Peripheral Residual Disease Monitoring Signals Progression Risk in Multiple Myeloma
10/18/2024
Jolynn Tumolo
Peripheral residual disease identified using next-generation flow in patients with transplant-eligible multiple myeloma was associated with a 13-fold increased risk of progression or death, according to a clinical trial update published...
Peripheral residual disease identified using next-generation flow in patients with transplant-eligible multiple myeloma was associated with a 13-fold increased risk of progression or death, according to a clinical trial update published...
Peripheral residual disease...
10/18/2024
First Report Managed Care
Dimopoulos
Conference Coverage
Advancing Treatment Options for High-Risk Multiple Myeloma
10/02/2024
Meletios-Athanasios Dimopoulos
Discover how the addition of daratumumab to standard treatment improves outcomes for patients with high-risk cytogenetic abnormalities in multiple myeloma according to a SOHO 2024 presenter.
Discover how the addition of daratumumab to standard treatment improves outcomes for patients with high-risk cytogenetic abnormalities in multiple myeloma according to a SOHO 2024 presenter.
Discover how the addition of...
10/02/2024
First Report Managed Care
Conference Insider
Early Data Show Fast, Deep Responses With Teclistamab-Based Regimen for Multiple Myeloma
04/13/2023
Maria Asimopoulos
Emma Searle, MD, PhD, reviews early data from MajesTEC-2, a trial designed to evaluate the recently approved monoclonal antibody teclistamab in combination with daratumumab and lenalidomide in patients with relapsed/refractory multiple...
Emma Searle, MD, PhD, reviews early data from MajesTEC-2, a trial designed to evaluate the recently approved monoclonal antibody teclistamab in combination with daratumumab and lenalidomide in patients with relapsed/refractory multiple...
Emma Searle, MD, PhD, reviews...
04/13/2023
First Report Managed Care
Conference Coverage
Oral, IV Multiple Myeloma Therapy Start Rates Significantly Increased During Pandemic
03/28/2023
Hannah Musick
Researchers speculated the increased therapy initiation rates may be explained by a significant decrease in the number of newly diagnosed patients.
Researchers speculated the increased therapy initiation rates may be explained by a significant decrease in the number of newly diagnosed patients.
Researchers speculated the...
03/28/2023
First Report Managed Care
Headshot of Dr Hira Shaikh, University of Iowa
Interview
Hispanic Ethnicity Associated With Worse Multiple Myeloma Outcomes, Study Shows
01/19/2023
Maria Asimopoulos
Hira Shaikh, MD, assistant professor of hematology, oncology, and bone marrow transplant, University of Iowa Hospitals and Clinics, walks through the details of her study which compared multiple myeloma survival outcomes among Hispanic vs...
Hira Shaikh, MD, assistant professor of hematology, oncology, and bone marrow transplant, University of Iowa Hospitals and Clinics, walks through the details of her study which compared multiple myeloma survival outcomes among Hispanic vs...
Hira Shaikh, MD, assistant...
01/19/2023
First Report Managed Care
News
Combination Therapy for Multiple Myeloma Emerging as Standard of Care
12/22/2022
Edan Stanley
Authors shared updated efficacy and safety data from the phase 3 CANDOR study in which patients with relapsed or refractory multiple myeloma were treated with two combination therapy options.
Authors shared updated efficacy and safety data from the phase 3 CANDOR study in which patients with relapsed or refractory multiple myeloma were treated with two combination therapy options.
Authors shared updated efficacy...
12/22/2022
First Report Managed Care
News
Stem Cell Yield Adequate for Transplant After 4 Cycles of Daratumumab, Lenalidomide Quadruplet Induction for MM
12/21/2022
Jolynn Tumolo
Researchers reviewed data from the MASTER and GRIFFIN trials to determine whether patients could undergo stem cell transplants after receiving induction therapy that included daratumumab and lenolidamide. 
Researchers reviewed data from the MASTER and GRIFFIN trials to determine whether patients could undergo stem cell transplants after receiving induction therapy that included daratumumab and lenolidamide. 
Researchers reviewed data from...
12/21/2022
First Report Managed Care
News
Real-World Treatment Patterns, Outcomes in Patients With Double- and Triple-Class R/R Multiple Myeloma
12/15/2022
Jolynn Tumolo
Researchers studied a heavily pretreated patient population to determine which drugs were being administered, as well as their impact on overall survival.
Researchers studied a heavily pretreated patient population to determine which drugs were being administered, as well as their impact on overall survival.
Researchers studied a heavily...
12/15/2022
First Report Managed Care
News
Combination Regimen Prolongs Overall Survival in Relapsed/Refractory Multiple Myeloma
12/08/2022
Jolynn Tumolo
The study participants received up to 8 cycles of bortezomib and dexamethasone, with or without daratumumab, until disease progression.
The study participants received up to 8 cycles of bortezomib and dexamethasone, with or without daratumumab, until disease progression.
The study participants received...
12/08/2022
First Report Managed Care
Literature Review
Anti-CD38 Monoclonal Antibody for Multiple Myeloma: A Review of Clinical Trials
11/29/2022
Maria Asimopoulos
Several ongoing and upcoming clinical trials are testing the efficacy and safety of a monoclonal antibody in combination with other therapies for multiple myeloma.
Several ongoing and upcoming clinical trials are testing the efficacy and safety of a monoclonal antibody in combination with other therapies for multiple myeloma.
Several ongoing and upcoming...
11/29/2022
First Report Managed Care
Headshot of Joshua Richter, MD, Mount Sinai
Interview
Analyzing First-line Therapy for Multiple Myeloma: Real-World Data Differs From Trials
10/18/2022
Maria Asimopoulos
Joshua Richter, MD, associate professor of medicine, hematology, and oncology, Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, reviews real-world data presented at the SOHO 2022 Annual Meeting in which combination bortezomib,...
Joshua Richter, MD, associate professor of medicine, hematology, and oncology, Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, reviews real-world data presented at the SOHO 2022 Annual Meeting in which combination bortezomib,...
Joshua Richter, MD, associate...
10/18/2022
First Report Managed Care

Newsfeed

News
Peripheral Residual Disease Monitoring Signals Progression Risk in Multiple Myeloma
10/18/2024
Jolynn Tumolo
Peripheral residual disease identified using next-generation flow in patients with transplant-eligible multiple myeloma was associated with a 13-fold increased risk of progression or death, according to a clinical trial update published...
Peripheral residual disease identified using next-generation flow in patients with transplant-eligible multiple myeloma was associated with a 13-fold increased risk of progression or death, according to a clinical trial update published...
Peripheral residual disease...
10/18/2024
First Report Managed Care
News
Combination Therapy for Multiple Myeloma Emerging as Standard of Care
12/22/2022
Edan Stanley
Authors shared updated efficacy and safety data from the phase 3 CANDOR study in which patients with relapsed or refractory multiple myeloma were treated with two combination therapy options.
Authors shared updated efficacy and safety data from the phase 3 CANDOR study in which patients with relapsed or refractory multiple myeloma were treated with two combination therapy options.
Authors shared updated efficacy...
12/22/2022
First Report Managed Care
News
Stem Cell Yield Adequate for Transplant After 4 Cycles of Daratumumab, Lenalidomide Quadruplet Induction for MM
12/21/2022
Jolynn Tumolo
Researchers reviewed data from the MASTER and GRIFFIN trials to determine whether patients could undergo stem cell transplants after receiving induction therapy that included daratumumab and lenolidamide. 
Researchers reviewed data from the MASTER and GRIFFIN trials to determine whether patients could undergo stem cell transplants after receiving induction therapy that included daratumumab and lenolidamide. 
Researchers reviewed data from...
12/21/2022
First Report Managed Care
News
Real-World Treatment Patterns, Outcomes in Patients With Double- and Triple-Class R/R Multiple Myeloma
12/15/2022
Jolynn Tumolo
Researchers studied a heavily pretreated patient population to determine which drugs were being administered, as well as their impact on overall survival.
Researchers studied a heavily pretreated patient population to determine which drugs were being administered, as well as their impact on overall survival.
Researchers studied a heavily...
12/15/2022
First Report Managed Care
News
Combination Regimen Prolongs Overall Survival in Relapsed/Refractory Multiple Myeloma
12/08/2022
Jolynn Tumolo
The study participants received up to 8 cycles of bortezomib and dexamethasone, with or without daratumumab, until disease progression.
The study participants received up to 8 cycles of bortezomib and dexamethasone, with or without daratumumab, until disease progression.
The study participants received...
12/08/2022
First Report Managed Care
News
Comparing Cost-Effectiveness of 3 Treatment Regimens for Multiple Myeloma
12/29/2021
Maria Asimopoulos
Combination lenalidomide plus dexamethasone was more cost-effective than 2 other treatment regimens in patients with multiple myeloma, though authors encouraged further analyses that include overall survival data.
Combination lenalidomide plus dexamethasone was more cost-effective than 2 other treatment regimens in patients with multiple myeloma, though authors encouraged further analyses that include overall survival data.
Combination lenalidomide plus...
12/29/2021
First Report Managed Care
News
Novel Multiple Myeloma Agents Can Add Years, but at High Costs
12/22/2021
Jolynn Tumolo
Researchers conducted a systematic review of multiple myeloma treatment options to "provide physicians, payers, and policy makers with the necessary information for evidence-based decision making to ensure accessibility to promising novel...
Researchers conducted a systematic review of multiple myeloma treatment options to "provide physicians, payers, and policy makers with the necessary information for evidence-based decision making to ensure accessibility to promising novel...
Researchers conducted a...
12/22/2021
First Report Managed Care
News
Triple Regimen for Relapsed/Refractory Multiple Myeloma Feasible in Frail Patients
12/15/2021
Jolynn Tumolo
A combination therapy demonstrated efficacy in frail older adults with relapsed/refractory multiple myeloma who had already received two or more therapies.
A combination therapy demonstrated efficacy in frail older adults with relapsed/refractory multiple myeloma who had already received two or more therapies.
A combination therapy...
12/15/2021
First Report Managed Care
News
Risk Factors Associated With Secondary Extramedullary Multiple Myeloma Development
12/08/2021
Jolynn Tumolo
Younger age, extensive bone disease, and other factors were linked to an increased risk of developing secondary extramedullary multiple myeloma, according to findings published online ahead of print.
Younger age, extensive bone disease, and other factors were linked to an increased risk of developing secondary extramedullary multiple myeloma, according to findings published online ahead of print.
Younger age, extensive bone...
12/08/2021
First Report Managed Care
News
Urban Residents With Arthritis Access More In-Person Care Than Rural Counterparts
04/24/2025
Lisa Kuhns, PhD, MD
Individuals with rheumatoid arthritis (RA) and osteoarthritis (OA) living in rural areas access significantly less in-person health care than those in urban settings, according to a study published in Arthritis Care & Research.
Individuals with rheumatoid arthritis (RA) and osteoarthritis (OA) living in rural areas access significantly less in-person health care than those in urban settings, according to a study published in Arthritis Care & Research.
Individuals with rheumatoid...
04/24/2025
First Report Managed Care
News
Continued Immunotherapy Beyond Progression May Extend Survival in Metastatic NSCLC
04/23/2025
Grace Taylor, MS, MA
Study finds extended survival with immunotherapy beyond disease progression for patients with non–small cell lung cancer.
Study finds extended survival with immunotherapy beyond disease progression for patients with non–small cell lung cancer.
Study finds extended survival...
04/23/2025
First Report Managed Care
News
New siRNA Shows Long-Term Efficacy and Enhanced Safety in Hemophilia A and B
04/21/2025
Grace Taylor, MS, MA
A long-term study reveals that fitusiran effectively rebalances hemostasis while reducing bleeding episodes in patients with hemophilia.
A long-term study reveals that fitusiran effectively rebalances hemostasis while reducing bleeding episodes in patients with hemophilia.
A long-term study reveals that...
04/21/2025
First Report Managed Care
News
Bone Health Screenings Underused in US Hemophilia Centers Despite High Risk
04/17/2025
Grace Taylor, MS, MA
Low screening rates for osteoporosis in people with hemophilia highlight a critical gap in preventative care at US federally funded hemophilia centers.
Low screening rates for osteoporosis in people with hemophilia highlight a critical gap in preventative care at US federally funded hemophilia centers.
Low screening rates for...
04/17/2025
First Report Managed Care
News
New Treatment for Vitiligo Offers Long-Term Cost Savings and High Repigmentation Success
04/14/2025
Lisa Kuhns, PhD, MD
A novel treatment for stable vitiligo combining autologous skin cell suspension (ASCS) with phototherapy has demonstrated both clinical success and long-term cost savings when compared to phototherapy alone, according to study results...
A novel treatment for stable vitiligo combining autologous skin cell suspension (ASCS) with phototherapy has demonstrated both clinical success and long-term cost savings when compared to phototherapy alone, according to study results...
A novel treatment for stable...
04/14/2025
First Report Managed Care
News
Fitusiran Shows Sustained Bleed Control and Safety With AT-Guided Dosing in Hemophilia
04/14/2025
Juliet Gallagher
Findings from a phase 2 open-label extension study suggest that fitusiran, a small interfering RNA (siRNA) therapy targeting antithrombin (AT), offers sustained bleeding control and quality of life improvements in people with moderate or...
Findings from a phase 2 open-label extension study suggest that fitusiran, a small interfering RNA (siRNA) therapy targeting antithrombin (AT), offers sustained bleeding control and quality of life improvements in people with moderate or...
Findings from a phase 2...
04/14/2025
First Report Managed Care
News
Fixed-Duration Mosunetuzumab Offers Effective and Budget-Friendly Option for Relapsed Follicular Lymphoma
04/14/2025
Lisa Kuhns, PhD, MD
Mosunetuzumab adds a highly effective, fixed-duration treatment option for patients with relapsed or refractory (R/R) follicular lymphoma (FL), with minimal financial impact to payers.
Mosunetuzumab adds a highly effective, fixed-duration treatment option for patients with relapsed or refractory (R/R) follicular lymphoma (FL), with minimal financial impact to payers.
Mosunetuzumab adds a highly...
04/14/2025
First Report Managed Care
News
Expert Panel Calls for Improved Utilization of Biosimilar Anti-TNF-α Therapies in IBD to Enable Earlier, More Effective Treatment
04/11/2025
Hannah Musick
Researchers urge for the broader use of biosimilar anti-TNF-α therapies in irritable bowel disease (IBD) to support earlier, more effective treatment and improve long-term outcomes, emphasizing the need for targeted clinician and patient...
Researchers urge for the broader use of biosimilar anti-TNF-α therapies in irritable bowel disease (IBD) to support earlier, more effective treatment and improve long-term outcomes, emphasizing the need for targeted clinician and patient...
Researchers urge for the broader...
04/11/2025
First Report Managed Care
News
Study Quantifies How Social and Structural Factors Drive Racial Inequities in NSCLC Care
04/11/2025
Lisa Kuhns, PhD, MD
Black patients with non-small cell lung cancer (NSCLC) in the US experience significantly worse care and outcomes compared with White patients, and these disparities are largely explained by exposure to structural racism across the health...
Black patients with non-small cell lung cancer (NSCLC) in the US experience significantly worse care and outcomes compared with White patients, and these disparities are largely explained by exposure to structural racism across the health...
Black patients with non-small...
04/11/2025
First Report Managed Care
News
MUSETTE Trial Confirms Optimal Dosing of Ocrelizumab for Relapsing MS
04/10/2025
Danielle Sposato
In a recent press release, Genentech has announced results from the phase 3 MUSETTE trial (NCT04544436), which evaluated higher doses of intravenous (IV) ocrelizumab (Ocrevus) in patients with relapsing multiple sclerosis (RMS).
In a recent press release, Genentech has announced results from the phase 3 MUSETTE trial (NCT04544436), which evaluated higher doses of intravenous (IV) ocrelizumab (Ocrevus) in patients with relapsing multiple sclerosis (RMS).
In a recent press release,...
04/10/2025
First Report Managed Care

Insights

Headshot of Dr Hira Shaikh, University of Iowa
Interview
Hispanic Ethnicity Associated With Worse Multiple Myeloma Outcomes, Study Shows
01/19/2023
Maria Asimopoulos
Hira Shaikh, MD, assistant professor of hematology, oncology, and bone marrow transplant, University of Iowa Hospitals and Clinics, walks through the details of her study which compared multiple myeloma survival outcomes among Hispanic vs...
Hira Shaikh, MD, assistant professor of hematology, oncology, and bone marrow transplant, University of Iowa Hospitals and Clinics, walks through the details of her study which compared multiple myeloma survival outcomes among Hispanic vs...
Hira Shaikh, MD, assistant...
01/19/2023
First Report Managed Care
Headshot of Joshua Richter, MD, Mount Sinai
Interview
Analyzing First-line Therapy for Multiple Myeloma: Real-World Data Differs From Trials
10/18/2022
Maria Asimopoulos
Joshua Richter, MD, associate professor of medicine, hematology, and oncology, Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, reviews real-world data presented at the SOHO 2022 Annual Meeting in which combination bortezomib,...
Joshua Richter, MD, associate professor of medicine, hematology, and oncology, Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, reviews real-world data presented at the SOHO 2022 Annual Meeting in which combination bortezomib,...
Joshua Richter, MD, associate...
10/18/2022
First Report Managed Care

Behind the Bill

Behind the Bill
The Medicare Paradox: How Tariffs Could Undermine IRA Drug Pricing Reforms
04/23/2025
Katie Hayes, MJ
The Trump administration's recent announcement of national security investigations into pharmaceutical imports has set up a potential collision course with one of the most significant health care reforms in recent years. While the White...
The Trump administration's recent announcement of national security investigations into pharmaceutical imports has set up a potential collision course with one of the most significant health care reforms in recent years. While the White...
The Trump administration's...
04/23/2025
First Report Managed Care
Behind the Bill
The Bitter Pill, Now in Motion: Pharma Tariffs Move from Rhetoric to Reality
04/16/2025
Katie Hayes, MJ
Last week, I flagged the growing risk that tariffs could upend affordability in the generics market. This week, the Trump administration made it official: it’s launching national security investigations under Section 232 of the Trade...
Last week, I flagged the growing risk that tariffs could upend affordability in the generics market. This week, the Trump administration made it official: it’s launching national security investigations under Section 232 of the Trade...
Last week, I flagged the growing...
04/16/2025
First Report Managed Care
Behind the Bill
The Bitter Pill: How Tariffs Could Make Generics Less Affordable
04/09/2025
Katie Hayes, MJ
As President Donald Trump’s administration introduces a series of tariffs aimed at rebalancing trade and boosting US manufacturing, one sector in particular is watching closely: pharmaceuticals. While drugs themselves may not be directly...
As President Donald Trump’s administration introduces a series of tariffs aimed at rebalancing trade and boosting US manufacturing, one sector in particular is watching closely: pharmaceuticals. While drugs themselves may not be directly...
As President Donald Trump’s...
04/09/2025
First Report Managed Care
Behind the Bill
SCOTUS Takes on the Nondelegation Doctrine: Surprising Reactions and What They Mean for Agency Power
04/02/2025
Katie Hayes, MJ
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard...
04/02/2025
First Report Managed Care
Behind the Bill
Dr Oz’s Prescription for Making Medicaid “Viable at Every Level”
03/26/2025
Katie Hayes, MJ
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the...
03/26/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question Continues: Dr Oz's Confirmation and the Future of Medicaid
03/19/2025
Katie Hayes, MJ
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880...
03/19/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question: Can Congress Cut Spending Without Touching Medicaid?
03/12/2025
Katie Hayes, MJ
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from...
03/12/2025
First Report Managed Care
Behind the Bill
RFK Jr’s Public Comment Ban: The Silent Shift in Health Care Rulemaking
03/05/2025
Katie Hayes, MJ
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative...
03/05/2025
First Report Managed Care
Behind the Bill
Prevention Over Pills? The First 2 Weeks of Health Care’s New Direction
02/26/2025
Katie Hayes, MJ
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from...
02/26/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 2)
02/19/2025
Katie Hayes, MJ
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the...
02/19/2025
First Report Managed Care

Subscribe and Stay Ahead With Daily Industry Insights

First Report Managed Care Newsletter

Trending Articles

News
Examining the Link Between Emergency Department Use and Insurance Coverage
05/26/2023
Julie Gould
“Although Medicaid expansion has provided increased health care coverage for many previously uninsured patients, prior literature suggests that health care utilization and public spending increase with government insurance coverage,” wrote...
“Although Medicaid expansion has provided increased health care coverage for many previously uninsured patients, prior literature suggests that health care utilization and public spending increase with government insurance coverage,” wrote...
“Although Medicaid expansion has...
05/26/2023
First Report Managed Care
News
CDC Data Shows Link Between High Costs and Prescription Nonadherence in Adults
06/21/2023
Julie Gould
In 2021, medication nonadherence among adults was associated with costs, gender, disability status, insurance coverage, and other characteristics.
In 2021, medication nonadherence among adults was associated with costs, gender, disability status, insurance coverage, and other characteristics.
In 2021, medication nonadherence...
06/21/2023
First Report Managed Care
News
Cell-Based Relative Potency Assay Assessed for RSV Vaccine Development
07/19/2023
Julie Gould
Researchers tested RSV mRNA vaccine V171 through a relative potency assay to assess its ability to induce humoral and cellular immunity responses. 
Researchers tested RSV mRNA vaccine V171 through a relative potency assay to assess its ability to induce humoral and cellular immunity responses. 
Researchers tested RSV mRNA...
07/19/2023
First Report Managed Care
News
Socioeconomic Status May Influence Brain Aging
08/11/2023
Hannah Musick
A recent study indicated that lower socioeconomic status is associated with premature brain aging and impacts cognition and resilience to neurological injury.
A recent study indicated that lower socioeconomic status is associated with premature brain aging and impacts cognition and resilience to neurological injury.
A recent study indicated that...
08/11/2023
First Report Managed Care
News
Strong Self-Identity, Accessibility Key for Self-Management of MS
09/06/2023
Jolynn Tumolo
The intricacies of socio-ecological factors that impact how individuals with multiple sclerosis (MS) manage their lifestyles are multifaceted, often converging around two primary elements: self-identity and accessibility.
The intricacies of socio-ecological factors that impact how individuals with multiple sclerosis (MS) manage their lifestyles are multifaceted, often converging around two primary elements: self-identity and accessibility.
The intricacies of...
09/06/2023
First Report Managed Care

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use